Marshall Wace’s Sutro Biopharma STRO Stock Holding History

Marshall Wace’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.55M	Buy	222,634 +137,019	+160%	+$2.48M	0.01%	1253
2025 Q4	$991K	Buy	85,615 +73,771	+623%	+$700K	﹤0.01%	1938
2025 Q3	$103K	Sell	11,844 -11,599	-49%	-$98.7K	﹤0.01%	2654
2025 Q2	$166K	Buy	+23,443	New	+$192K	﹤0.01%	2483
2024 Q4	–	Sell	-3,066	Closed	-$106K	–	2990
2024 Q3	$106K	Buy	+3,066	New	+$120K	﹤0.01%	2368
2023 Q2	–	Sell	-21,791	Closed	-$1.01M	–	2949
2023 Q1	$1.01M	Sell	21,791 -34,201	-61%	-$2.17M	﹤0.01%	1807
2022 Q4	$4.52M	Buy	55,992 +3,630	+7%	+$252K	0.01%	1253
2022 Q3	$2.91M	Sell	52,362 -5,062	-9%	-$300K	0.01%	1776
2022 Q2	$2.99M	Buy	+57,424	New	+$3.21M	0.01%	1715
2021 Q3	–	Sell	-11,490	Closed	-$2.14M	–	3413
2021 Q2	$2.14M	Sell	11,490 -20,554	-64%	-$4.02M	0.01%	1379
2021 Q1	$7.29M	Buy	32,044 +734	+2%	+$174K	0.03%	624
2020 Q4	$6.8M	Buy	+31,310	New	+$5.18M	0.04%	468

Other funds holding STRO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Marshall Wace's STRO Position: Q1 2026 in Review

Marshall Wace increased its Sutro Biopharma (STRO) stake by 160% in Q1 2026, buying an estimated $2.48M and bringing the position to 222,634 shares worth $5.55M. The position accounts for 0.01% of the portfolio, ranked #1253.

Marshall Wace first reported a position in STRO in Q4 2020 and has held it in 12 quarters since. The position peaked at $7.29M in Q1 2021. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

Marshall Wace held 222,634 shares of Sutro Biopharma worth $5.55M as of Q1 2026.
Marshall Wace bought 137,019 Sutro Biopharma shares in Q1 2026, an estimated $2.48M.
Sutro Biopharma made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1253 holding.
Marshall Wace first reported a position in Sutro Biopharma in Q4 2020 and has held it in 12 quarters since.
Marshall Wace's Sutro Biopharma position peaked at $7.29M in Q1 2021.
78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.